Dupixent, manufactured by Sanofi, has a price that can vary significantly based on factors such as insurance coverage, patient assistance programs, and the specific indication for which it is prescribed [1]. The list price for Dupixent is generally high, reflecting the cost of developing and manufacturing a novel biologic therapy.
How much does Dupixent typically cost without insurance?
Without insurance, the monthly cost of Dupixent can range from approximately $3,500 to $4,500 or more. This price is for a typical monthly supply, which may consist of two pre-filled syringes [2].
What financial assistance is available for Dupixent?
Sanofi offers several patient assistance programs to help reduce the out-of-pocket costs for eligible individuals. These include:
* Dupixent MyWay Savings Card: This program offers co-pay assistance for commercially insured patients, potentially lowering monthly costs to as little as $5 for a limited time [3].
* Patient Assistance Program (PAP): For uninsured or underinsured patients who meet specific income criteria, Sanofi may provide Dupixent at no cost or at a significantly reduced price [4].
How does insurance affect Dupixent pricing?
Insurance coverage plays a crucial role in determining a patient's actual cost for Dupixent. Many insurance plans cover Dupixent, but patients may still face deductibles, co-pays, and co-insurance. The formulary status of Dupixent on a particular insurance plan can also influence its accessibility and cost [2]. Prior authorization from insurance providers is often required before approving coverage.
What is the price of Dupixent for different conditions?
The price of Dupixent is generally consistent across its approved indications, which include moderate-to-severe atopic dermatitis, moderate-to-severe asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis [1]. While the dosage may vary slightly depending on the condition, the list price of the medication itself remains relatively stable.
When can generic versions of Dupixent become available?
Dupixent is a biologic drug, and as such, it is not subject to traditional generic competition. Instead, biosimilars may be developed and approved. The patent and exclusivity landscape for Dupixent is complex and involves multiple patents protecting different aspects of the drug [5]. DrugPatentWatch.com tracks these patents, which can provide insights into potential future biosimilar entry dates, though the exact timeline for biosimilar availability is subject to patent challenges and regulatory approvals [5].